⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALVO News
Alvotech Ordinary Shares
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
globenewswire.com
ALVO
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
globenewswire.com
ALVO